Immunai

Why the immune system is the bottleneck

The same cancer drug saves one patient and does nothing for another, and the difference often lies in each person's immune state. Immunai, founded in 2018 by Noam Solomon (CEO) and Luis Voloch (CTO), built its work around a combination of two technologies: single-cell sequencing, which makes it possible to measure tens of thousands of immune cells individually instead of a rough average of a whole sample, and machine learning that draws patterns from these measurements.

A research tool for the drug industry, not a clinical product

The output is a large-scale immune database, and models that try to answer practical questions in drug development: who is likely to respond to a treatment, what mechanism makes a drug work or fail, and which biological targets are worth testing. The company works with large pharmaceutical companies, not with patients. On 15 January 2026 Immunai announced a collaboration with Bristol Myers Squibb: it will use its AI platform, AMICA-OS, to analyze immune data from BMS clinical studies, to understand why different patients respond differently to the same therapy.

What Immunai itself announced about the $215 million round

On 27 October 2021 Immunai published an official announcement titled "Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform": a $215 million Series B round, which brought its total funding to $295 million, led by Koch Disruptive Technologies. The announcement quotes both founders. Noam Solomon: "We have made great progress towards our core mission of understanding the immune system"; and Luis Voloch: "The ability of our platform to surface and evaluate new drug targets has given us the confidence to push into therapeutic development".

What Immunai itself announced about the AstraZeneca collaboration

On 16 October 2025 Immunai published, on its official newsroom page (immunai.com/newsroom), an announcement of an agreement with AstraZeneca to advance a therapeutic target for inflammatory bowel disease (IBD), worth up to $85 million. The announcement quotes Immunai CEO Noam Solomon: "Using an unbiased approach powered by AI and machine learning, Immunai's platform has identified an exciting novel target for IBD". The collaboration between the companies began back in 2022, and in 2024 AstraZeneca committed a further $18 million to use the platform in oncology trials.

What is not here yet

It is important to say plainly what does not exist: there is no drug, no diagnostic and no direct clinical use. This is an early stage in the chain: reducing risk and shortening time in the research stages. As of 2026 it has not yet been shown that a drug developed with the help of approaches like this reached the market significantly faster. Most of the field's revenue still comes from collaborations with drug companies, not from a standalone product.